CIK 0001680581
- Non-accelerated filer
- Smaller reporting company
Fulcrum Therapeutics, Inc.
Sign in to watch- Ticker
- FULC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 474839948
- Phone
- +1 617-651-8851
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-01 | Dunn Judith | Grant or award · Stock Option (right to buy) | +215,000 | 215,000 | ||
| 2021-03-31 | Stuart Bryan | Grant or award · Stock Option (right to buy) | +350,000 | 350,000 | ||
| 2021-03-16 | Gould Robert J | Sale | −789 | $12.43 | $10K | 506,630 |
| 2021-03-15 | Gould Robert J | Sale | −9,211 | $12.13 | $112K | 507,419 |
| 2021-02-22 | Thomson Peter G. VP Finance & Accounting | Exercise or conversion | +5,000 | $7.84 | $39K | 20,212 |
| 2021-02-22 | Thomson Peter G. VP Finance & Accounting | Sale | −5,000 | $14.72 | $74K | 15,212 |
| 2021-02-22 | Thomson Peter G. VP Finance & Accounting | Exercise or conversion · Stock Option (right to buy) | −5,000 | 50,471 | ||
| 2021-02-16 | Gould Robert J | Sale | −6,542 | $14.19 | $93K | 518,303 |
| 2021-02-16 | Gould Robert J | Sale | −1,673 | $14.56 | $24K | 516,630 |
| 2021-02-08 | Moxham Christopher Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2021-02-02 | Gould Robert J | Grant or award · Stock Option (right to buy) | +269,390 | 269,390 | ||
| 2021-01-25 | Stuart Bryan Chief Operating Officer | Grant or award · Stock Option (right to buy) | +134,376 | 134,376 | ||
| 2021-01-25 | Thomson Peter G. VP Finance & Accounting | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-01-21 | Thomson Peter G. VP Finance & Accounting | Sale | −6,607 | $14.00 | $92K | 15,212 |
| 2021-01-20 | Gould Robert J | Sale | −10,000 | $12.08 | $121K | 524,845 |
| 2020-12-03 | Ezekowitz Alan Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2020-12-03 | Oltmans Curtis Gale SVP, General Counsel | Grant or award · Stock Option (right to buy) | +153,600 | 153,600 | ||
| 2020-09-14 | Wallace Owen B. Chief Scientific Officer | Exercise or conversion | +6,350 | $7.84 | $50K | 133,438 |
| 2020-09-14 | Wallace Owen B. Chief Scientific Officer | Exercise or conversion · Stock Option (right to buy) | −6,350 | 75,592 | ||
| 2020-07-08 | Wallace Owen B. Chief Scientific Officer | Exercise or conversion | +2,951 | $7.84 | $23K | 130,039 |
Page 9 of 15 · 291 trades